GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nyrada Inc (ASX:NYR) » Definitions » Current Accrued Expense

Nyrada (ASX:NYR) Current Accrued Expense : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Nyrada Current Accrued Expense?

Nyrada's Current Accrued Expense for the quarter that ended in Dec. 2023 was A$0.00 Mil.


Nyrada Current Accrued Expense Historical Data

The historical data trend for Nyrada's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyrada Current Accrued Expense Chart

Nyrada Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
Current Accrued Expense
- - - - -

Nyrada Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Current Accrued Expense Get a 7-Day Free Trial - - - - -

Nyrada Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


Nyrada Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Nyrada's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Nyrada (ASX:NYR) Business Description

Industry
Traded in Other Exchanges
N/A
Address
828 Pacific Highway, Suite 2, Level 3, Gordon, NSW, AUS, 2072
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.

Nyrada (ASX:NYR) Headlines

No Headlines